Diethylcarbamazine activity against Brugia malayi microfilariae is dependent on inducible nitric-oxide synthase and the cyclooxygenase pathway

Helen F McGarry, Leigh D Plant, Mark J Taylor, Helen F McGarry, Leigh D Plant, Mark J Taylor

Abstract

Background: Diethylcarbamazine (DEC) has been used for many years in the treatment of human lymphatic filariasis. Its mode of action is not well understood, but it is known to interact with the arachidonic acid pathway. Here we have investigated the contribution of the nitric oxide and cyclooxygenase (COX) pathways to the activity of DEC against B. malayi microfilariae in mice.

Methods: B. malayi microfilariae were injected intravenously into mice and parasitaemia was measured 24 hours later. DEC was then administered to BALB/c mice with and without pre-treatment with indomethacin or dexamethasone and the parasitaemia monitored. To investigate a role for inducible nitric oxide in DEC's activity, DEC and ivermectin were administered to microfilaraemic iNOS-/- mice and their background strain (129/SV). Western blot analysis was used to determine any effect of DEC on the production of COX and inducible nitric-oxide synthase (iNOS) proteins.

Results: DEC administered alone to BALB/c mice resulted in a rapid and profound reduction in circulating microfilariae within five minutes of treatment. Microfilarial levels began to recover after 24 hours and returned to near pre-treatment levels two weeks later, suggesting that the sequestration of microfilariae occurs independently of parasite killing. Pre-treatment of animals with dexamethasone or indomethacin reduced DEC's efficacy by almost 90% or 56%, respectively, supporting a role for the arachidonic acid and cyclooxygenase pathways in vivo. Furthermore, experiments showed that treatment with DEC results in a reduction in the amount of COX-1 protein in peritoneal exudate cells. Additionally, in iNOS-/- mice infected with B. malayi microfilariae, DEC showed no activity, whereas the efficacy of another antifilarial drug, ivermectin, was unaffected.

Conclusion: These results confirm the important role of the arachidonic acid metabolic pathway in DEC's mechanism of action in vivo and show that in addition to its effects on the 5-lipoxygenase pathway, it targets the cyclooxygenase pathway and COX-1. Moreover, we show for the first time that inducible nitric oxide is essential for the rapid sequestration of microfilariae by DEC.

Figures

Figure 1
Figure 1
DEC causes rapid sequestration of B. malayi microfilariae in BALB/c mice. BALB/c mice intravenously injected with B. malayi microfilariae were dosed orally with 100 mg/kg DEC and microfilaraemia monitored from 5 to 60 minutes post treatment, then at 24 hours and two weeks.
Figure 2
Figure 2
Indomethacin or dexamethasone pre-treatment reduces efficacy of DEC in BALB/c mice infected with B. malayi microfilariae. Indomethacin (10 mg/kg), dexamethasone (3 mg/kg) or vehicle was administered 30 minutes before oral dosing with DEC (100 mg/kg). Symbols are means of three mice for the DEC plus dexamethasone group (triangles), seven mice for the DEC plus indomethacin group (white circles) and four mice for the DEC-only group (black circles). Significantly different results from the DEC-only group are denoted by * (P < 0.017), ** (P = 0.001) or *** (P = 0.000).
Figure 3
Figure 3
DEC is ineffective against B. malayi microfilariae in the absence of iNOS. Efficacy of (a) a single, oral dose of DEC (100 mg/kg) or (b) a single, i.p. dose of ivermectin phosphate (1 mg/kg) in 129/SV and iNOS-/- mice infected with B. malayi microfilariae. Black symbols represent 129/SV mice, white symbols iNOS-/-. Squares indicate DEC administration, triangles ivermectin administration and circles untreated controls. Symbols represent mean results from at least three or four mice, except in the case of those treated with ivermectin (two animals) from two combined experiments which were representative of a further repeat. Significantly different microfilaraemias between 129/SV and iNOS-/- mice after DEC administration are denoted by * (P = 0.001) or ** (P = 0.000).
Figure 4
Figure 4
Western blot detection of COX-1 protein from peritoneal exudate cells. COX-1 protein was detected in 129/SV and iNOS-/- peritoneal exudate cells thirty minutes after i.p. injection of endotoxin-free water (control) or DEC (10 mg/kg). Proteins (10 μg) were separated on a 7.5% denaturing SDS polyacrylamide gel, transferred to PVDF membrane, incubated with rabbit anti-mouse COX-1, then goat anti-rabbit IgG-horse radish peroxidase conjugate and detected by chemiluminescence.

References

    1. Molyneux DH, Bradley M, Hoerauf A, Kyelem D, Taylor MJ. Mass drug treatment for lymphatic filariasis and onchocerciasis. Trends Parasitol. 2003;19:516–522. doi: 10.1016/j.pt.2003.09.004.
    1. Hawking F, Laurie W. Action of hetrazan on filariasis and onchocerciasis. Lancet. 1949;2:146–147. doi: 10.1016/S0140-6736(49)90993-9.
    1. Vickery AC, Nayar JK, Tamplin ML. Diethylcarbamazine-mediated clearance of Brugia pahangi microfilariae in immunodeficient nude mice. Am J Trop Med Hyg. 1985;34:476–483.
    1. Maizels RM, Denham DA. Diethylcarbamazine (DEC): immunopharmacological interactions of an anti-filarial drug. Parasitol. 1992;105:S49–S60.
    1. Needleman P, Turk J, Jakschik BA, Morrison AR, Lefkowith JB. Arachidonic acid metabolism. Ann Rev Biochem. 1986;55:69–102. doi: 10.1146/annurev.bi.55.070186.000441.
    1. Bach MK, Brashler JR. Inhibition of the leukotriene synthetase of rat basophil leukemia cells by diethylcarbamazine, and synergism between diethylcarbamazine and piriprost, a 5-lipoxygenase inhibitor. Biochem Pharmacol. 1986;31:2129–2132.
    1. Mathews WR, Murphy RC. Inhibition of leukotriene biosynthesis in mastocytoma cells by diethylcarbamazine. Biochem Pharmacol. 1982;31:2129–2132. doi: 10.1016/0006-2952(82)90435-X.
    1. Kanesa-Thasan N, Douglas JG, Kazura JW. Diethylcarbamazine inhibits endothelial and microfilarial prostanoid metabolism in vitro. Mol Biochem Parasitol. 1991;49:11–20. doi: 10.1016/0166-6851(91)90125-P.
    1. King CH, Greene BM, Spagnuolo PJ. Diethylcarbamazine citrate, an antifilarial drug, stimulates human granulocyte adherence. Antimicr Ag Chemo. 1983;24:453–456.
    1. Rácz P, Tenner-Rácz K, Büttner DW, Albiez EJ. Ultrastructural evidence for eosinophil-parasite adherence (EPA) reaction in human onchocercal lymphadenitis in the early period following diethylcarbamazine treatment. Tropenmed Parasitol. 1982;33:213–218.
    1. Medina-De la Garza CE, Brattig NW, Tischendorf FW, Jarrett JMB. Serum-dependent interaction of granulocytes with Onchocerca volvulus microfilariae in generalized and chronic hyper-reactive onchocerciasis and its modulation by diethylcarbamazine. Trans R Soc Trop Med Hyg. 1990;84:701–706. doi: 10.1016/0035-9203(90)90155-8.
    1. Clancy RM, Abramson SB. Nitric oxide: a novel mediator of inflammation. Proc Soc Exp Biol Med. 1995;210:93–101.
    1. Sano H, Hla T, Maier JAM, Crofford LJ, Case JP, Maciag T, Wilder RL. In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J Clin Invest. 1992;89:97–108.
    1. Salvemini D. Regulation of cyclooxygenase enzymes by nitric oxide. Cell Mol Life Sci. 1997;53:576–582. doi: 10.1007/s000180050074.
    1. Clancy R, Varenika B, Huang W, Ballou L, Attur M, Amin AR, Abramson SB. Nitric oxide synthase/COX cross-talk: nitric oxide activates COX-1 but inhibits COX-2-derived prostaglandin production. J Immunol. 2000;165:1582–1587.
    1. Horii Y, Aoki Y. Plasma levels of diethylcarbamazine and their effects on implanted microfilariae of Brugia pahangi in rats. J Vet Med Sci. 1997;59:961–963. doi: 10.1292/jvms.59.961.
    1. Denham DA, Suswillo RR, Rogers R, McGreevy PB. Studies with Brugia pahangi 17. The anthelmintic effects of diethylcarbamazine. J Parasitol. 1978;64:463–468.
    1. Neill M, Kazura JW. The effect of diethylcarbamazine in a murine model of Brugia malayi microfilaraemia. Bull WHO. 1979;57:329–330.
    1. Taylor MJ, Cross HF, Mohammed AA, Trees AJ, Bianco AE. Susceptibility of Brugia malayi and Onchocerca lienalis microfilariae to nitric oxide and hydrogen peroxide in cell-free culture and from IFNτ-activated macrophages. Parasitol. 1996;112:315–322.
    1. Rajan TV, Shultz LD, Babu S, Doukas J, Greiner D, Porte P. Diethylcarbamazine (DEC) does not induce nitric oxide (NO) synthesis. Exp Parasitol. 1998;88:217–222. doi: 10.1006/expr.1998.4247.
    1. Salvemini D, Misko TP, Masferrer JL, Seibert K, Currie MG, Needleman P. Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci USA. 1993;90:7240–7244.
    1. Salvemini D, Seibert K, Masferrer JL, Misko TP, Currie MG, Needleman P. Endogenous nitric oxide enhances prostaglandin production in a model of renal inflammation. J Clin Invest. 1994;93:1940–1947.
    1. Salvemini D, Settle SL, Masferrer JL, Seibert K, Currie MG, Needleman P. Regulation of prostaglandin production by nitric oxide; an in vivo analysis. Br J Pharmacol. 1995;114:1171–1178.
    1. Devaux Y, Seguin C, Grosjean S, de Talancé N, Camaeti V, Burlet A, Zannad F, Meistelman C, Moertes P-M, Longrois D. Lipopolysaccharide-induced increase of prostaglandin E2 is mediated by inducible nitric oxide synthase activation of the constitutive cyclooxygenase and induction of membrane-associated prostaglandin E synthase. J Immunol. 2001;167:3962–3971.
    1. Marnett LJ, Wright TL, Crews BC, Tannenbaum SR, Morrow JD. Regulation of prostaglandin biosynthesis by nitric oxide is revealed by targeted deletion of inducible nitric-oxide synthase. J Biol Chem. 2000;275:13427–13430. doi: 10.1074/jbc.275.18.13427.
    1. Swierkosz TA, Mitchell JA, Warner TD, Botting RM, Vane JR. Co-induction of nitric oxide synthase and cyclo-oxygenase: interactions between nitric oxide and prostanoids. Br J Pharmacol. 1995;114:1335–1342.
    1. Reddy ST, Tiano HF, Langenbach R, Morham SG, Herschman HR. Genetic evidence for distinct roles of COX-1 and COX-2 in the immediate and delayed phases of prostaglandin synthesis in mast cells. Biochem Biophys Res Comm. 1999;265:205–210. doi: 10.1006/bbrc.1999.1658.
    1. Bozza PT, Payne JL, Morham SG, Langenbach R, Smithies O, Weller PF. Leukocyte lipid body formation and eicosanoid generation: cyclooxygenase-independent inhibition by aspirin. Proc Natl Acad Sci USA. 1996;93:11091–11096. doi: 10.1073/pnas.93.20.11091.
    1. Hobbs MR, Udhayakumar V, Levesque MC, Booth J, Roberts JM, Tkachuk AN, Pole A, Coon H, Kariuki S, Nahlen BL, Mwaikambo ED, Lal AL, Granger DL, Anstey NM, Weinberg JB. A new NOS2 promoter polymorphism associated with increased nitric oxide production and protection from severe malaria in Tanzanian and Kenyan children. Lancet. 2002;360:1468–1475. doi: 10.1016/S0140-6736(02)11474-7.
    1. Kun JF, Mordmuller B, Perkins DJ, May J, Mercereau-Puijalon O, Alpers M, Weinberg JB, Kremsner PG. Nitric oxide synthase 2 (Lambarene) (G-954C), increased nitric oxide production, and protection against malaria. J Inf Dis. 2001;184:330–336. doi: 10.1086/322037.
    1. Ohashi J, Naka I, Patarapotikul J, Hananantachai H, Looareesuwan S, Tokunaga K. Significant association of longer forms of CCTTT microsatellite repeat in the inducible nitric oxide synthase promoter with severe malaria in Thailand. J Inf Dis. 2002;186:578–581. doi: 10.1086/341779.
    1. Rutherford S, Johnson MP, Curtain RP, Griffiths LR. Chromosome 17 and the inducible nitric oxide synthase gene in human essential hypertension. Hum Genet. 2001;109:408–415. doi: 10.1007/s004390100565.
    1. Cesbron JY, Capron A, Vargaftig BB, Lagarde M, Pincemail J, Braquet P, Taelman H, Joseph M. Platelets mediate the action of diethylcarbamazine on microfilariae. Nature. 1987;325:533–6. doi: 10.1038/325533a0.
    1. Chen LY, Mehta JL. Further evidence of the presence of constitutive and inducible nitric oxide synthase isoforms in human platelets. J Cardiovasc Pharmacol. 1996;27:154–8. doi: 10.1097/00005344-199601000-00024.
    1. Mehta JL, Chen LY, Kone BC, Mehta P, Turner P. Identification of constitutive and inducible forms of nitric oxide synthase in human platelets. J Lab Clin Med. 1995;125:370–7.
    1. Liu LX, Serhan CN, Weller PF. Intravascular filarial parasites elaborate cyclooxygenase-derived eicosanoids. J Exp Med. 1990;172:993–996. doi: 10.1084/jem.172.3.993.
    1. Liu LX, Buhlmann JE, Weller PF. Release of prostaglandin E2 by microfilariae of Wuchereria bancrofti and Brugia malayi. Am J Trop Med Hyg. 1992;46:520–523.
    1. Kaiser L, Lamb VL, Tithof PK, Gage DA, Chamberlin BA, Watson JT, Williams JF. Dirofilaria immitis : do filarial cyclooxygenase products depress endothelium-dependent relaxation in the in vitro rat aorta? Exp Parasitol. 1992;75:159–167. doi: 10.1016/0014-4894(92)90175-A.
    1. Sommer A, Rickert R, Fischer P, Steinhart H, Walter RD, Liebau E. A dominant role for extracellular glutathione S-transferase from Onchocerca volvulus is the production of Prostaglandin D2. Infect Immun. 2003;71:3603–3606. doi: 10.1128/IAI.71.6.3603-3606.2003.
    1. Liu LX, Weller PF. Intravascular filarial parasites inhibit platelet aggregation. Role of parasite-derived prostanoids. J Clin Invest. 1992;89:1113–1120.
    1. Liu LX, Weller PF. Arachidonic acid metabolism in filarial parasites. Exp Parasitol. 1990;71:496–501. doi: 10.1016/0014-4894(90)90076-O.
    1. Peixoto CA, Rocha A, Aguiar-Santos A. The effects of diethylcarbamazine on the ultrastructure of microfilariae of Wuchereria bancrofti in vivo and in vitro. Parasitol Res. 2004;92:513–517. doi: 10.1007/s00436-004-1081-0.

Source: PubMed

3
Abonnere